̽����ѡ

was founded in 2000 by some of Sweden’s leading oncological, clinical and ̽����ѡ researchers. The innovation behind Oncopeptides builds on the development of a cytotoxin that searches for and targets a specific type of cancer cell. However, the development phase took longer than expected due to uncertainty surrounding its effectiveness.

“We then came into contact with the leading multiple myeloma research group at the Dana-Farber Cancer Institute, , that was able to confirm our results. They saw so much potential in the project that they wanted to take control of it completely. This spurred interest among Swedish investors and accelerated the pace of our work,” explains , professor of oncology at ̽����ѡ, and consultant at Karolinska University Hospital.

Capital was soon raised in Sweden to conduct Phase 1 and Phase 2 trials in co-operation with, among others, the Dana-Farber Cancer Institute.

Clinicians as a driving force

During Oncopeptides’ first three years of operation, Lewensohn served as CEO.

“It was an instructive journey that provided entirely new perspectives on the opportunities of achieving clinical benefit from discoveries, and showed how we can meet the university’s third responsibility, namely to work with society and industry.”

“One of the strengths behind Oncopeptides was that development was led by clinicians,” he says.

“This was a virtually unique situation because as it was us heading-up the project, we understood the potential that lay in the use of the drug. It was a major advantage to have awareness of the patient’s perspective.”

Oncopeptides was listed in 2017, and work is now underway on the upcoming Phase 3 clinical trial.

“We had early contact with KI Innovations who supported us with investment and contributed to business development and provided advice. We currently anticipate having a new drug ready in the next couple of years,” says Lewensohn.